跳至主要内容
临床试验/CTRI/2019/08/020979
CTRI/2019/08/020979尚未招募2 期

Phase II non-randomized open clinical evaluation of Siddha drug VELLI PARPAM for PITHA MOOTHIRA KIRICHARAM (Benign prostate hypertrophy) in Male between 40 to 80 age group attending OPD at AAGHIM attached with GSMC

Govt Siddha Medical College1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2019年5月9日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
20
试验地点
1
主要终点
Reduced in clinical symptoms using IPSS assessing scale

研究概览

简要总结

This is a Non randomized open clinical trial to study safety and efficacy of siddha drug VELLI PARPAM. The drug is given 130 mg once a day for 48 days. Clinical trial will be started after completion of preclinical and toxicological study. the drug VELLI PARPAM mentioned in siddhar kai kanda marunthu written by Balaramiya. During the trial all the study related data will be recorded and documented.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
40.00 Year(s) 至 80.00 Year(s)(—)
性别
Male

入选标准

  • Isolated BPH symptoms BPH with lower urinary tract symptoms PSA (prostate specific antigen) with in the normal limit (<4nm/ml).
  • USG prostate volume not more than 75 cc ( stage I – 25 cc to 50 cc and stage II – 50 cc to 75 cc).

排除标准

  • Age < 40 and > 80 yrs male Acute urinary retention CA prostate Acute and chronic renal failure Diabetic nephropathy Post TURP states Stricture urethra Urinary bladder calculus Any severe life threatening illness Nephrotic and nephritic syndrome PSA more than 4 nm/ml [5].
  • USG Prostate volume more than 80CC Acute pyelonephritis Obstructive uropathy Prostatitis.

结局指标

主要结局

Reduced in clinical symptoms using IPSS assessing scale

时间窗: 48 days

次要结局

  • Monitoring the reduction in the size of the gland from stage II to stage I and from stage I to normal using ultrasonography(48 days)

研究者

发起方
Govt Siddha Medical College
申办方类型
Government medical college

研究点 (1)

Loading locations...

相似试验

Clinical evaluation of Siddha drug Velli parpam for... | 临床试验